Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various geneti… Read more
Feng Chi Biotech Corp. (6744) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.007x
Based on the latest financial reports, Feng Chi Biotech Corp. (6744) has a cash flow conversion efficiency ratio of -0.007x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-1.67 Million) by net assets (NT$233.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Feng Chi Biotech Corp. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Feng Chi Biotech Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Feng Chi Biotech Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Feng Chi Biotech Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WANdisco plc
PINK:WANSF
|
-0.675x |
|
Transition Metals Corp
PINK:TNTMF
|
-0.209x |
|
TERADYNE
MU:TEY
|
0.057x |
|
Accuracy Shipping Limited
NSE:ACCURACY
|
0.085x |
|
TJGC Group Limited
NASDAQ:TJGC
|
-0.140x |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
0.000x |
|
Mec Resources Ltd
AU:MMR
|
-0.047x |
|
Chaoprayamahanakorn Public Company Limited
BK:CMC
|
0.012x |
Annual Cash Flow Conversion Efficiency for Feng Chi Biotech Corp. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Feng Chi Biotech Corp. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$239.88 Million | NT$25.05 Million | 0.104x | +61.22% |
| 2023-12-31 | NT$238.00 Million | NT$15.41 Million | 0.065x | -46.38% |
| 2022-12-31 | NT$235.87 Million | NT$28.49 Million | 0.121x | -15.43% |
| 2021-12-31 | NT$230.51 Million | NT$32.92 Million | 0.143x | -18.16% |
| 2020-12-31 | NT$225.08 Million | NT$39.28 Million | 0.175x | +57.89% |
| 2019-12-31 | NT$213.55 Million | NT$23.61 Million | 0.111x | -- |